ALSO NOTED: Novartis 4Q profit down 45%; Sanofi: Dr. Reddy's won't launch Plavix copy;

> Novartis' restructuring cut deeply into fourth-quarter profits, with a $444 million charge bringing earnings down to $931 million from $1.6 billion during the same quarter last year. Report

> Sanofi-Aventis said it's "highly unlikely" that India's Dr. Reddy's would launch a generic version of Sanofi's anti-clotting drug Plavix in the U.S. Report

> Japan's Eisai cleared an antitrust obstacle to its buyout of MGI Pharma; the $41 per share tender offer expires next week. Report

> The FDA warned today that two different drugs commonly referred to as EDTA--edetate disodium and edetate calcium disodium--should not be confused; both children and adults have died when given the wrong one. Report

> Pfizer has once again demonstrated its zeal for biotech, inking a $250 million deal to in-license the worldwide rights to an experimental osteoarthritis therapy under development at Germany's Scil Technology. Report

> Dr. Judah Folkman (photo)--whose work on angiogenesis spawned a new category of oncology drugs--died on Monday at the age of 74. Report

> Forecast: Biotech and pharmaceutical outsourcing will grow '08. Report

And Finally... First hormone therapy and now calcium supplements? What's a post-menopausal woman to do? Report

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.